BGIM
MRVI icon

Boussard & Gavaudan Investment Management’s Maravai LifeSciences MRVI Stock Holding History

Boussard & Gavaudan Investment Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-160,617
Closed -$4.46K – 155
2022
Q2 		$4.46K Buy
+160,617
New +$5.09M 0.81% 36

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCBV
Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Boussard & Gavaudan Investment Management's MRVI Position: Q3 2022 in Review

Boussard & Gavaudan Investment Management sold out of Maravai LifeSciences (MRVI) in Q3 2022, closing a stake of 160,617 shares — an estimated $4.46K sold.

Boussard & Gavaudan Investment Management first reported a position in MRVI in Q2 2022 and held it in 1 quarter. The position peaked at $4.46K in Q2 2022. 202 funds tracked by Wall St. Rank hold MRVI as of Q3 2022.

  • Boussard & Gavaudan Investment Management reported no remaining Maravai LifeSciences position as of Q3 2022 after selling out during the quarter.
  • Boussard & Gavaudan Investment Management sold 160,617 Maravai LifeSciences shares in Q3 2022, an estimated $4.46K.
  • Boussard & Gavaudan Investment Management first reported a position in Maravai LifeSciences in Q2 2022 and held it in 1 quarter.
  • Boussard & Gavaudan Investment Management's Maravai LifeSciences position peaked at $4.46K in Q2 2022.
  • 202 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2022.

Based on Boussard & Gavaudan Investment Management's 13F filing for Q3 2022, filed 9 Nov 2022.